Literature DB >> 8607388

Atrial fibrillation: maintenance of sinus rhythm versus rate control.

S M Sopher1, A J Camm.   

Abstract

Atrial fibrillation represents a common and challenging arrhythmia. A rational approach to management of the individual case depends on careful assessment of the temporal of the arrhythmia, any associated cardiovascular disease, and any particular features suggesting the advisability or risks of any particular treatment regimen. The nature of an arrhythmia and of individual patient factors change over time, requiring a flexible approach to long-term treatment that may be defined only after months or years. While new treatment options such as catheter ablation techniques and implantable atrial defibrillators are being tested, old therapies (e.g., low-dose amiodarone) are undergoing reappraisal. Increasing recognition of the dangers of antiarrhythmic therapy used to maintain sinus rhythm is focusing attention on nonpharmacologic methods. All patients with persistent atrial fibrillation merit serious consideration for direct current cardioversion before accepting that atrial fibrillation is permanent, and many patients may benefit from more than one attempt to restore and maintain sinus rhythm.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8607388     DOI: 10.1016/s0002-9149(97)89115-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

Review 1.  [Cardiology update. I: Electrophysiology].

Authors:  P Weismüller; H J Trappe
Journal:  Med Klin (Munich)       Date:  1999-01-15

Review 2.  Atrial fibrillation: is rate stabilization a valid clinical strategy?

Authors:  S H Hohnloser
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-04       Impact factor: 1.468

3.  Determination of the target ventricular rate in patients with atrial fibrillation by evaluation of ventriculoarterial coupling.

Authors:  Sachihiko Nobuoka; Seiji Hatano; Junzo Nagashima; Akihiro Yoshida; Hisanobu Adachi; Yukiko Imai; Masaaki Shibamoto; Kyoko Ikeda; Fumihiko Miyake
Journal:  Tex Heart Inst J       Date:  2002

Review 4.  When, and when not, to use digoxin in the elderly.

Authors:  A T Gosselink; D J van Veldhuisen; H J Crijns
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

Review 5.  Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment.

Authors:  Giuseppe Boriani; Cristian Martignani; Mauro Biffi; Alessandro Capucci; Angelo Branzi
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Success of Radiofrequency Catheter Ablation of Atrial Fibrillation: Does Obesity Influence the Outcomes?

Authors:  Dhanunjaya R Lakkireddy; George E Blake; Dimpi Patel; Martin Rotter; Atul Verma; Kay Ryschon; Mohammed Khan; Robert Schweikert; Michel Haissaguerre; Andrea Natale
Journal:  J Atr Fibrillation       Date:  2008-05-16

Review 7.  [Pharmacological cardioversion of atrial fibrillation].

Authors:  J R Ehrlich; S H Hohnloser
Journal:  Z Kardiol       Date:  2005-01

Review 8.  Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.

Authors:  Gerald V Naccarelli; John Hynes; Deborah L Wolbrette; Luna Bhatta; Mazhar Khan; Jerry Luck
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

9.  Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations?

Authors:  Eleni Hatzinikolaou-Kotsakou; Zarifis Kartasis; Dimitrios Tziakas; Athanasios Hotidis; Dimitrios Stakos; Konstantinos Tsatalas; Georgios Bourikas; Maria E Kotsakou; Dimitrios I Hatseras
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

10.  Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation.

Authors:  L Obergassel; T Lawrenz; F H Gietzen; F Lieder; C Leuner; H Kuhn; C Stellbrink
Journal:  Clin Res Cardiol       Date:  2006-03-21       Impact factor: 6.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.